Expression of acetylated and Dimethylated Histone h3 in colorectal cancer

Digestive Surgery

Volumn 30, Issue 3, 2013, Pages 249-258

  Hashimoto, Toshio ^a   Yamakawa, Mitsunori ^a   Kimura, Shingo ^a   Usuba, Osamu ^a   Toyono, Mitsuru ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Acetylated histone H3; Chromatin immunoprecipitation; Colorectal cancer; Dimethylated histone H3; Prognosis; Western blot assay

Indexed keywords

HISTONE;

ACETYLATION; ADENOCARCINOMA; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CHEMISTRY; CHROMATIN IMMUNOPRECIPITATION; COLORECTAL TUMOR; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; METABOLISM; METHYLATION; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR INVASION; WESTERN BLOTTING;

ACETYLATION; ADENOCARCINOMA; AGED; BLOTTING, WESTERN; CHROMATIN IMMUNOPRECIPITATION; COLORECTAL NEOPLASMS; FEMALE; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; METHYLATION; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84880999731     PISSN: 02534886     EISSN: None     Source Type: Journal    
DOI: 10.1159/000351444     Document Type: Article

References (30)

1. Baylin SB, Ohm JE: Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006; 6: 107-116
2. Bird AP: CpG-rich islands and the function of DNA methylation. Nature 1986; 321: 209-213
3. Ozdaǧ H, Teschendorff AE, Ahmed AA, Hyland SJ, Blenkiron C, Bobrow L, Veerakumarasivam A, Burtt G, Subkhankulova T, Arends MJ, Collins VP, Bowtell D, Kouzarides T, Brenton JD, Caldas C: Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 2006; 7: 90
4. Martin DG, Grimes DE, Baetz K, Howe L: Methylation of histone H3 mediates the association of the NuA3 histone acetyltransferase with chromatin. Mol Cell Biol 2006; 26: 3018-3028
5. Yan C, Boyd DD: Histone H3 acetylation and H3K4 methylation define distinct chromatin regions permissive for transgene expression. Mol Cell Biol 2006; 26: 6357-6371
6. Minucci S, Pelicci PG: Histone deacetylase inhibitor and the promise of epigenetic (and more) treatment for cancer. Nat Rev Cancer 2006; 6: 38-51
7. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK: Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005; 435: 1262- 1266
8. Park YS, Jin MY, Kim YJ, Yook JH, Kim BS, Jang SJ: The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann Surg Oncol 2008; 15: 1968-1976
9. Tzao C, Tung HJ, Jin JS, Sun GH, Hsu HS, Chen BH, Yu CP, Lee SC: Prognostic significance of global histone modifications in resected squamous cell carcinoma of the esophagus. Mod Pathol 2009; 22: 252-260
10. Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, Wang Q, Chia D, Goodglick L, Kurdistani SK: Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 2009; 174: 1619-1628
11. Barlesi F, Giaccone G, Gallegos-Ruiz MI, Loundou A, Span SW, Lefesvre P, Kruyt FA, Rodriguez JA: Global histone modifications predict prognosis of resected non-small-cell lung cancer. J Clin Oncol 2007; 25: 4358-4364
12. Hoseok I, Eunkyung K, Yujin K, Eun YC, Joungho Han JP, Kwhanmien K, Duk HK, Young MS: Association of global levels of histone modifications with recurrence-free survival in stage IIB and III esophageal squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev 2010; 19: 566-573
13. Somaia EE, Andrew RG, Emad AR, Des GP, Rabab AA, Hilary MC, Daniele S, Jonathan MG, Claire EP, Amr AA, Matthew JG, Graham RB, Magdy KA, Luisa MP, David MH, Ian OE: Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res 2009; 69: 3802-3809
14. Tamagawa H, Oshima T, Manabu Shiozawa M, Morinaga S, Nakamura Y, Yoshihara M, Sakuma Y, Kameda Y, Akaike M, Masuda M, Imada T, Miyagi Y: The global histone modification pattern correlates with overall survival in metachronous liver metastasis of colorectal cancer. Oncol Rep 2012; 27: 637-642
15. Rogenhofer S, Kahl P, Holzapfel S, Von Ruecker A, Mueller SC, Ellinger J: Decreased levels of histone H3K9me1 indicate poor prognosis in patients with renal cell carcinoma. Anticancer Res 2012; 32: 879-886
16. Nakazawa T, Kondo T, Ma D, Niu D, Mochizuki K, Kawasaki T, Yamane T, Iino H, Fujii H, Katoh R: Global histone modification of histone H3 in colorectal cancer and its precursor lesions. Hum Pathol 2012; 43: 834-842
17. Okitsu CY, Hsieh CL: DNA methylation dictates histone H3K4 methylation. Mol Cell Biol 2007; 27: 2746-2757
18. Jass JR, Sobin LH, Watanabe H: World Health Organization - International Classification of Tumors: Histological Typing of Intestinal Tumors. Springer, New York, 1989
19. Sobin LH, Wittekind C (eds): TMN Classification of Malignant Tumors (ed 6). New York, Wiley, 2002
20. Handa K, Yamakawa M, Takeda H, Kimura S, Takahashi T: Expression of cell cycle markers in colorectal carcinoma: superiority of cyclin A as an indicator of poor prognosis. Int J Cancer 1999; 84: 225-233
21. Allred DC, Harvey JM, Berardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-168
22. Lee S, Mohsin SK, Mao S, Hilsenbeck SG, Medina D, Allred DC: Hormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer. Breast Cancer Res 2006; 8:R6
23. Andre T, Boni C, Mounedji BL, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah FI, de Gramont A; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351
24. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116
25. Nirmalan NJ, Harnden P, Selby PJ, Banks RE: Development and validation of a novel protein extraction methodology for quantitation of protein expression in formalin-fixed paraffin- embedded tissues using Western blotting. J Pathol 2009; 217: 497-506
26. Grantzdorffer I, Yumlu S, Gioeva Z, von Wasielewski R, Ebert MP, Rocken C: Comparison of different tissue sampling methods for protein extraction from formalin-fixed and paraffin-embedded tissue specimens. Exp Mol Pathol 2009; 88: 190-196
27. Mizutani K, Miki H, He H, Maruta H, Takenawa T: Essential role of neural Wiskott-Aldrich syndrome protein in podosome formation and degradation of extracellular matrix in src -transformed fibroblasts. Cancer Res 2002; 62: 669-674
28. Luo RX, Postigo AA, Dean D: Rb interacts with histone deacetylase to repress transcription. Cell 1998; 92: 463-473
29. Strahl BD, Allis CD: The language of covalent histone modifications. Nature 2000; 403: 41- 45
30. Schreiber SL, Bernstein BE: Signaling network model of chromatin. Cell 2002; 111: 771- 778.